Dashboard
Manage Tickers

AGIO AGIOS PHARMACEUTICALS, INC.


$ 24.18 $ -0.50 (-2.03 %)    

Friday, 21-Nov-2025 11:16:09 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 584.07 $ -3.26 (-0.56 %)
DIA $ 459.64 $ 0.23 (0.05 %)
SPY $ 653.54 $ -1.49 (-0.23 %)
TLT $ 89.39 $ -0.27 (-0.3 %)
GLD $ 374.25 $ 0.27 (0.07 %)
$ 24.57
$ 24.52
$ 24.13 x 275
$ 24.19 x 11
$ 23.02 - $ 24.62
$ 22.24 - $ 62.45
7,666,286
na
1.43B
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-nasdaq-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This Nasdaq Analyst Turns Bullish; Here Ar...
11/20/2025 17:14:47

rbc-capital-downgrades-agios-pharmaceuticals-to-sector-perform-lowers-price-target-to-28
RBC Capital Downgrades Agios Pharmaceutica...
11/20/2025 14:56:28

RBC Capital analyst Luca Issi downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Outperform to Sector Perform and lowers th...

this-bellring-brands-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Bellring Brands Analyst Is No Longer ...
11/20/2025 14:09:44

b-of-a-securities-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-32
B of A Securities Maintains Buy on Agios P...
11/20/2025 12:51:55

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target...

leerink-partners-upgrades-agios-pharmaceuticals-to-outperform-lowers-price-target-to-34
Leerink Partners Upgrades Agios Pharmaceut...
11/20/2025 12:50:24

Leerink Partners analyst Andrew Berens upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Market Perform to Outperform and lo...

goldman-sachs-maintains-neutral-on-agios-pharmaceuticals-lowers-price-target-to-25
Goldman Sachs Maintains Neutral on Agios P...
11/20/2025 12:48:29

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price targ...

nvidia-to-rally-around-72-here-are-10-top-analyst-forecasts-for-thursday
Nvidia To Rally Around 72%? Here Are 10 To...
11/20/2025 11:58:27

hc-wainwright--co-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-48
HC Wainwright & Co. Maintains Buy on Agios...
11/20/2025 10:08:21

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price t...

crude-oil-falls-over-2-lowes-shares-gain-after-q3-results
Crude Oil Falls Over 2%; Lowe's Shares Gai...
11/19/2025 17:58:53

why-is-agios-pharmaceuticals-stock-sinking-today
Why Is Agios Pharmaceuticals Stock Sinking...
11/19/2025 17:30:29

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises,...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
11/19/2025 17:06:03

agios-pharmaceuticals-says-topline-results-from-rise-up-phase-3-trial-of-mitapivat-for-sickle-cell-disease-met-its-primary-endpoint-of-hemoglobin-response-while-mitapivat-did-not-achieve-statistical-significance-on-the-annualized-rate-of-sickle-cell-pain-crises-compared-to-placebo
Agios Pharmaceuticals Says Topline Results...
11/19/2025 12:06:10

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentrati...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
11/19/2025 12:05:44

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

agios-pharmaceuticals-q3-eps-178-beats-191-estimate-sales-12880m-beat-10417m-estimate
Agios Pharmaceuticals Q3 EPS $(1.78) Beats...
10/30/2025 10:35:30

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of...

earnings-outlook-for-agios-pharmaceuticals
Earnings Outlook For Agios Pharmaceuticals
10/29/2025 19:02:33

reported-earlier-agios-pharmaceuticals-receives-chmps-opinion-for-the-new-indication-for-pyrukynd-the-european-commission-will-now-review-the-chmps-opinion-with-the-final-decision-expected-by-early-2026
Reported Earlier: Agios Pharmaceuticals Re...
10/17/2025 15:27:48

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceut...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target
HC Wainwright & Co. Reiterates Buy on Agio...
09/04/2025 16:04:25

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use
FDA Delays Decision On Agios Pharmaceutica...
09/04/2025 14:49:53

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION